126 results on '"West, Michael L."'
Search Results
2. Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease
3. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
4. Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
5. Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products
6. Lentivirus-mediated gene therapy for Fabry disease
7. Initiation of pharmacologic chaperone therapy for Fabry disease in the Canadian Fabry Disease Initiative (CFDI) registry is not associated with reduction of kidney function
8. Switch from enzyme replacement therapy to pharmacologic chaperone: Improvement in advanced Fabry nephropathy
9. Chest pain subtype prevalence in the British Columbia cohort of the Canadian Fabry Disease Initiative
10. Facilitating intrafamily communication to enable earlier diagnosis of Fabry disease in relatives: Expert opinion
11. FollowME Fabry Pathfinders Registry: Renal effectiveness in a cohort of patients on migalastat treatment for at least three years
12. Retrospective review of recent ASA prescribing practices for primary prevention of major adverse cardiovascular events in the Canadian Fabry Disease Initiative cohort
13. Glycosphingolipid evaluation for Fabry disease patients receiving migalastat after switching from enzyme replacement therapy
14. Fabry disease biomarkers in patients switched from enzyme-replacement therapy to migalastat oral chaperone therapy.
15. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease
16. How well does urinary lyso-Gb 3 function as a biomarker in Fabry disease?
17. Gender-specific plasma proteomic biomarkers in patients with Anderson–Fabry disease
18. Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease.
19. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis
20. The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.
21. Primary Hyperoxaluria Type 1 (PH1) Presenting With End-Stage Kidney Disease and Cutaneous Manifestations in Adulthood: A Case Report.
22. Cardio-renal outcomes with long-term alfa enzyme replacement therapy : a 10-year Fabry outcome survey (FOS) analysis
23. Patients with Fabry disease on dialysis in the United States
24. Renal-Limited Antiglomerular Basement Membrane Disease Related To Alemtuzumab: A Case Report.
25. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
26. Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.
27. Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction.
28. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
29. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease.
30. Early therapy in Fabry disease: Outcomes from the Canadian Fabry Disease Initiative (CFDI) registry.
31. Uncertain Diagnosis of Fabry Disease in Patients with Neuropathic Pain, Angiokeratoma or Cornea Verticillata: Consensus on the Approach to Diagnosis and Follow-Up.
32. Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease
33. A novel method for solid-phase synthesis of oligosaccharides using the N-1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde) linker
34. A modification of the urine osmolal gap: an improved method for estimating urine ammonium.
35. A renal mechanism limiting the degree of potassium loss in severely hyperglycemic patients.
36. Renal potassium handling during states of low aldosterone bio-activity: a method to differentiate renal and non-renal causes.
37. Possible Role of the Intestinal P‐450 Enzyme System in a Cyclosporine‐Clarithromycin Interaction.
38. Valvular heart disease complicating advanced Fabry disease: Association with chronic kidney disease.
39. Canadian Fabry disease registry study group: Report on the A143P Nova Scotia genotype.
40. Lyso Gb3 and Gb3 analogues in Fabry disease patients with A143P genotype: A cross-sectional analysis by the CFDR study group.
41. Cardiovascular Events in Patients With Fabry Disease Natural History Data From the Fabry Registry
42. Total synthesis of (+-)-calanolide A, a non-nucleoside inhibitor of HIV-1 reverse transcriptase.
43. The spectrum of podocyte injury in later onset (LO) variants of Fabry disease (FD).
44. Dde as a Protecting Group for Carbohydrate Synthesis.
45. Solid-Phase Oligosaccharide Chemistry and Its Application to Library Synthesis.
46. BRONCHIOLITIS OBLITERANS AND ORGANIZING PNEUMONIA IN RENAL TRANSPLANT RECIPIENTS.
47. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing.
48. Determination of the crystal structure and substrate specificity of ananain.
49. Corrigendum to "Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing" [2021 Sep-Oct;134(1–2):117–131].
50. Early initiation of agalsidase alfa treatment improves clinical outcomes in male patients with classical Fabry disease: A Fabry Outcome Survey (FOS) analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.